8-K: ESSA Pharma Advances XenoTherapeutics Merger with Court Application for Shareholder Cash Distribution

ESSA Pharma Inc. announced its intent to seek a British Columbia Supreme Court order on August 5, 2025, to facilitate its merger with XenoTherapeutics, including an initial cash distribution to shareholders.

Summary

• ESSA Pharma Inc. is proceeding with its previously announced business combination agreement, under which non-profit biotechnology company XenoTherapeutics, Inc. will acquire all of ESSA's issued and outstanding common shares.
• The company intends to apply to the Supreme Court of British Columbia on August 5, 2025, for an interim order to authorize a special meeting for shareholders to consider and approve the transaction.
• ESSA also seeks a court order to make an initial cash distribution to its shareholders prior to the closing of the transaction.
• The total estimated distribution to each ESSA shareholder, including the initial cash distribution and cash payable upon closing, is approximately US$1.91 per Common Share, exclusive of any contingent value rights payments.
• The application for the initial cash distribution aims to expedite the distribution of cash to ESSA shareholders.
• The court hearing for these orders is scheduled for August 5, 2025, at 9:45 a.m. Pacific time in Vancouver, British Columbia.
• ESSA plans to file its Petition Record on July 31, 2025, and response materials from affected parties are due by 1:00 p.m. Vancouver time on July 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company is taking concrete, expected steps towards completing a previously announced merger and expediting cash distribution to shareholders, which provides clarity and a defined return for investors. While risks are present, they are standard for such transactions and are clearly disclosed.

Positives

• The company is actively progressing towards the completion of the previously announced business combination, providing clarity on the transaction timeline.
• The intent to make an initial cash distribution to shareholders prior to closing aims to expedite the return of capital, which is beneficial for shareholders.
• The estimated total cash distribution of approximately US$1.91 per Common Share provides a clear financial expectation for shareholders from the transaction.

Risks

• The completion of the transaction is subject to various conditions, including obtaining required securityholder, regulatory, and court approvals, and there is no guarantee it will occur on anticipated terms or timing.
• Potential litigation related to the transaction could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers, which could impact the transaction's outcome.
• Disruptions from the transaction may harm ESSA's business, including current plans and operations.
• The ability to retain and hire key personnel during the transaction period is uncertain.
• There is a risk of potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction.
• Continued availability of capital and financing, as well as rating agency actions, could affect the company's financial position.
• Legislative, regulatory, and economic developments could impact ESSA's business.
• The accuracy of ESSA's financial projections is subject to inherent uncertainties.
• General business, market, and economic conditions could adversely affect the transaction.
• Certain restrictions during the pendency of the transaction may impact ESSA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, or outbreaks of war or hostilities, could affect the transaction.
• Significant transaction costs are associated with the business combination.
• The transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the transaction could arise.
• Risks and uncertainties pertaining to ESSA's business are detailed in its Annual Report on Form 10-K dated December 17, 2024, and will be further discussed in the Proxy Statement.

Future Outlook

The company anticipates the completion of the business combination with XenoTherapeutics, subject to obtaining necessary securityholder, regulatory, and court approvals. It expects to make an initial cash distribution to shareholders prior to the transaction's closing, with a total estimated distribution of approximately US$1.91 per common share.

Management Comments

• Management is actively pursuing court orders to facilitate the business combination and expedite cash distribution to shareholders.

Industry Context

This announcement reflects a strategic shift for ESSA Pharma, a company previously focused on prostate cancer therapies, as it moves towards being acquired by XenoTherapeutics, a non-profit biotechnology company. This type of acquisition, particularly involving a non-profit entity, can represent a unique form of consolidation or asset divestiture within the biotech sector, potentially allowing ESSA's assets or intellectual property to be utilized under a different operational model.

Comparison to Industry Standards

• This filing primarily details procedural steps for a pre-announced merger and cash distribution, rather than operational or financial performance. Therefore, direct comparisons to industry-standard financial metrics or project results of comparable companies are not applicable based on the content provided.
• The estimated cash distribution of US$1.91 per share is specific to this transaction and cannot be directly benchmarked against general industry M&A valuations without detailed financial context of both ESSA and XenoTherapeutics, which is not provided in this filing.

Legal Proceedings

• ESSA Pharma Inc. intends to apply to the Supreme Court of British Columbia on August 5, 2025, for an interim order authorizing a special meeting to approve the transaction and an order authorizing an initial cash distribution to shareholders.
• Potential litigation relating to the transaction could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.

Stakeholder Impact

• Shareholders are expected to receive an estimated total of US$1.91 per Common Share, with an initial portion potentially distributed prior to the transaction closing, providing a clear financial outcome.
• The transaction and associated disruptions may impact the ability to retain and hire key personnel, affecting employees.
• Business relationships may experience adverse reactions or changes due to the announcement or completion of the transaction, potentially impacting customers and suppliers.

Next Steps

• ESSA will file its Petition Record with the Supreme Court of British Columbia on July 31, 2025.
• The Supreme Court of British Columbia will hold a hearing on August 5, 2025, to consider the interim order for a special meeting and the order for an initial cash distribution.
• A special meeting of shareholders will be held to consider and approve the transaction, following court authorization.
• The company will file a Proxy Statement with the SEC, which will contain more detailed information about the proposed transaction.

Key Dates

Recommendation

The filing provides a procedural update on a previously announced acquisition, confirming the company's progress towards completing the merger and distributing cash to shareholders. For investors who have already taken a position based on the initial merger announcement, this update reinforces the expected outcome and timeline. There is no new fundamental information that would warrant a change in investment thesis, but rather confirmation of the path to realizing the previously communicated shareholder value.

Keywords

ESSA Pharma, XenoTherapeutics, Merger, Acquisition, Business Combination, Cash Distribution, Shareholder Value, Prostate Cancer, Biotechnology, SEC Filing, 8-K, Court Order, NASDAQ: EPIX